mFOLFIRINOX Clinical Trials
16 recruitingDrug
Phase 212Phase 16Phase 33
Showing 1–16 of 16 trials
Recruiting
Phase 1
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.77 enrolled5 locationsNCT07166601
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled37 locationsNCT06179160
Recruiting
Phase 2
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE105 enrolled10 locationsNCT07255404
Recruiting
Phase 1
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaCancer of the Pancreas
Washington University School of Medicine51 enrolled1 locationNCT06648434
Recruiting
Phase 2
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Phase 2 StudyBMS-986504MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center60 enrolled1 locationNCT07283705
Recruiting
Phase 2
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Pancreas AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences64 enrolled1 locationNCT05825066
Recruiting
Phase 2Phase 3
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Colon Cancer Stage III
Chungnam National University Hospital308 enrolled1 locationNCT05179889
Recruiting
Phase 2
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Rectum Cancer
Menoufia University100 enrolled1 locationNCT06812728
Recruiting
Phase 1Phase 2
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Pancreas Cancer
Zhejiang University63 enrolled1 locationNCT06572813
Recruiting
Phase 2
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School57 enrolled1 locationNCT06389760
Recruiting
Phase 2
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
Pancreatic Adenocarcinoma
Hamilton Health Sciences Corporation30 enrolled1 locationNCT04452461
Recruiting
Phase 2Phase 3
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Oncotelic Inc.455 enrolled2 locationsNCT06079346
Recruiting
Phase 1
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Locally Advanced Rectal Cancer
Gustave Roussy, Cancer Campus, Grand Paris78 enrolled2 locationsNCT05912075